Nonhomologous end-joining (NHEJ) plays a central role in regulation of cancer radiotherapy as well as genome editing
Dr. Zhou’s lab at Yale identified LRRC31 as a master regulator of the NHEJ machinery
The Zhou lab demonstrated that targeted upregulation of LRRC31 sensitizes tumors to irradiation and improves the efficiency of CRISPR-mediated precise genome editing
Intellectual Property: A patent application pending
Reference: Chen Y. et al. LRRC31 inhibits DNA repair and sensitizes breast cancer brain metastasis to radiation therapy, Nature Cell Biology. 2020, 22(10):1276-1285
